Obesity & OverweightNCT07245979
Supplementation With Sirtuin Activators in Women With Increased Body Weight
A study testing Sirtuin activators in people with Obesity & Overweight, run by Poznan University of Life Sciences at 1 site in Poland.
Trial summary
The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are: Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect… Read more about this study
- Who is it for?
- Ages 40 to 65 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Obesity & Overweight
- What is being tested?
- Sirtuin activators
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 120 participants
- Where
- 1 sitePoland
- Study dates
- 8 Oct 2025to 1 Mar 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- females
- age: 40-65 years
- overweight or obese: BMI >25 kg/m2
Who cannot join
- males
- BMI < 25 kg/m2
- sirtuin activators administration for 3 months prior to study
- pregnancy or breastfeeding
- recent dieting or being on calorie restricted diet
- receiving pharmacotherapy to treat obesity, diabetes or hyperlipidemia
Show all 11Show fewer
- post-bariatric surgery
- diabetes
- cancer
- chronic kidney, liver or autoimmune diseases
- alcohol addiction
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Poland1 site, 1 recruiting
- Recruiting
Poznan University of Life Sciences
Poznan
Agata Chmurzynska, Professor, +486184661, agata.chmurzynska@up.poznan.pl
Emilia Zawieja
About this study
Official title: Assessment of the Effect of Sirtuin Activator Supplementation on Cellular, Metabolic and Anthropometric Parameters in Women
The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:
Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?
Researchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.
Participants will:
Take sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.
- Conditions
- Obesity & Overweight
- Being tested
- Sirtuin activators, Placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sirtuin activatorsDietary supplement
Sirtuin acitivators supplementation for 6 months
PlaceboDietary supplement
Placebo supplementation for 6 months
| Study group | Role | What they receive |
|---|---|---|
| Experimental: sirtuin activators | Experimental | Sirtuin activators supplementation for 6 months, daily dose of 1278 mg, taken twice a day in a capsulated form. Daily dose will contain: resveratrol - 500 mg, leucin - 467 mg, Epigallocatechin gallate - 100 mg, quercetin - 100 mg, curcuminoids - 100 mg, niacin 10.7 mg. Daily number of capsules will be 2 x 2 = 4. Receives: Dietary Supplement: Sirtuin activators |
| Placebo comparator: placebo | Placebo comparator | Placebo will be an inactive substance (maltodextrin) provided in the same-looking capsules as sirtuin activators. Placebo will be administered twice a day, daily number of capsules will be 2 x 2 = 4. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Concentrations of blood lipids
Total cholesterol, Triacyglycerols, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesteroll
Measured: 6 months, two measurements: at month 0 and 6
Blood glucose concentrations
Blood glucose concentration
Measured: 6 months, two measurements: at month 0 and 6
Ageing biomarkers: transcription level of the p16INK4a gene in peripheral blood mononuclear cells
transcription level of the p16INK4a gene in peripheral blood mononuclear cells
Measured: 6 months, two measurements: at month 0 and 6
Ageing biomarkers: telomere lenght
telomere lenght measured in DNA isolated from whole blood
Measured: 6 months, two measurements: at month 0 and 6
Ageing biomarkers: SA beta galactosidase activity
SA beta galactosidase activity
Measured: 6 months, two measurements: at month 0 and 6
Oxidative stress
activities of oxidative stress enzymes in blood
Measured: 6 months, two measurements: at month 0 and 6
Secondary outcomes (4)
Body mass
Measured in kg
Measured: 6 months, two measurements: at month 0, 3 and 6
Body composition
Body composition will include percent body fat and lean body mass measured with air displacement plethysmography
Measured: 6 months, two measurements: at month 0, 3 and 6
Waist and hips circumference
Measured in cm
Measured: 6 months, two measurements: at month 0, 3 and 6
Genotype analyisis of the Sirt1 gene
Nucleotite variants at certain genomic position will be analysed
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start8 Oct 2025
- Primary completion30 Nov 2026 (estimated)
- Study completion1 Mar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obesity & OverweightStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Poznan University of Life Sciences
- Sponsor type
- University, hospital or other
- Collaborators
- Poznan University of Medical Sciences, NutroPharma
- Responsible party
- Principal investigator, Agata Chmurzyńska, Poznan University of Life Sciences
- Investigators
- Agata Chmurzynska, Professor, Principal investigator, Poznan Univeristy of Life Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07245979
- Sponsor's protocol ID
- Sirt activators
- Status last verified
- Feb 2026
- First submitted
- 2 Oct 2025
- Last updated
- 22 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment of the Effect of Sirtuin Activator Supplementation on Cellular, Metabolic and Anthropometric Parameters in Women
- ClinicalTrials.gov ID
- NCT07245979
- Acronym / sponsor ID
- Sirt activators
- Conditions
- Obesity & Overweight
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- Poznan University of Life SciencesUniversity, hospital or other
- Collaborators
- Poznan University of Medical Sciences, NutroPharma
- Study start
- 8 Oct 2025 (actual)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 1 Mar 2027 (estimated)
- First posted
- 24 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if the six-month supplementation with sirtuin activators can affect metabolism in 40-to-65-year old women with increased body weight. The main questions it aims to answer are:
Does sirtuin activators affect lipid and carbohydrate metabolism? Does sirtuin activators affect oxydative stress, immune functions and cell ageing?
Researchers will compare sirtuin activators to a placebo (a look-alike substance that contains no drug) to see if drug sirtuin activators works to improve metabolic status.
Participants will:
Take sirtuin activators or a placebo every day for 6 months. Visit the university once every 3 months for checkups and tests.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental: sirtuin activators | Experimental | Dietary Supplement: Sirtuin activatorsSirtuin activators supplementation for 6 months, daily dose of 1278 mg, taken twice a day in a capsulated form. Daily dose will contain: resveratrol - 500 mg, leucin - 467 mg, Epigallocatechin gallate - 100 mg, quercetin - 100 mg, curcuminoids - 100 mg, niacin 10.7 mg. Daily number of capsules will be 2 x 2 = 4. |
| Placebo comparator: placebo | Placebo comparator | Dietary Supplement: PlaceboPlacebo will be an inactive substance (maltodextrin) provided in the same-looking capsules as sirtuin activators. Placebo will be administered twice a day, daily number of capsules will be 2 x 2 = 4. |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- females
- age: 40-65 years
- overweight or obese: BMI >25 kg/m2
Key exclusion criteria (11 listed)
- males
- BMI < 25 kg/m2
- sirtuin activators administration for 3 months prior to study
- pregnancy or breastfeeding
- recent dieting or being on calorie restricted diet
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sirtuin activatorsSirtuin acitivators supplementation for 6 months | Dietary supplement | Experimental: sirtuin activators |
| PlaceboPlacebo supplementation for 6 months | Dietary supplement | Placebo comparator: placebo |
Primary outcome
Concentrations of blood lipids
Time frame: 6 months, two measurements: at month 0 and 6
Total cholesterol, Triacyglycerols, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesteroll
Blood glucose concentrations
Time frame: 6 months, two measurements: at month 0 and 6
Blood glucose concentration
Ageing biomarkers: transcription level of the p16INK4a gene in peripheral blood mononuclear cells
Time frame: 6 months, two measurements: at month 0 and 6
transcription level of the p16INK4a gene in peripheral blood mononuclear cells
Ageing biomarkers: telomere lenght
Time frame: 6 months, two measurements: at month 0 and 6
telomere lenght measured in DNA isolated from whole blood
Ageing biomarkers: SA beta galactosidase activity
Time frame: 6 months, two measurements: at month 0 and 6
SA beta galactosidase activity
Oxidative stress
Time frame: 6 months, two measurements: at month 0 and 6
activities of oxidative stress enzymes in blood
4 secondary outcomes
Body mass
Time frame: 6 months, two measurements: at month 0, 3 and 6
Body composition
Time frame: 6 months, two measurements: at month 0, 3 and 6
Waist and hips circumference
Time frame: 6 months, two measurements: at month 0, 3 and 6
Genotype analyisis of the Sirt1 gene
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2026.
- Individual participant dataSharing planned: No
Related trials for Obesity & Overweight
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Agata Chmurzynska, Professor principal investigator
Poznan Univeristy of Life Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sirtuin activators in people with Obesity & Overweight, run by Poznan University of Life Sciences at 1 site in Poland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Agata Chmurzynska, Professor (+486184661, agata.chmurzynska@up.poznan.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Concentrations of blood lipids (time frame: 6 months, two measurements: at month 0 and 6). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2026.